Novartis looks forward to presenting data from the company’s expansive hematology portfolio at the upcoming 61st American Society of Hematology Annual Meeting & Exposition (ASH), taking place December 7-10 in Orlando, Florida. More than 140 abstracts will be presented, demonstrating our growing pipeline of differentiated immunotherapies and our bold ambition to research and develop medicines that transform the standard of care for patients.
“Our data at ASH are evidence of the hard work, dedication and pioneering mindset of our teams. Novartis is deeply committed to build on its deep legacy in hematology to provide new innovative treatments and solutions that help people with malignant and benign blood disorders live longer, better lives,” said Susanne Schaffert, PhD, President, Novartis Oncology.
Novartis plans to provide updates around the 2019 ASH Annual Meeting on Novartis.com, Twitter, Facebook and LinkedIn, delving into the core of our commitment to reimagining medicine, including interviews with the scientists, people and principles behind our innovation; insights on new findings and developments, and breaking news.
